Synthace Team
First ever no-code platform lowers barriers to automated biological experimentation and insight sharing.
Ming Liu
Our Visual Design Lead, Ming Liu, shares some insights into redesigning a product for a new company and how this works in biotech.
Synthace hires Guy Levy-Yurista as Chief Executive Officer.
Strong financial performance and achievement of other key milestones demonstrate the growing strength of Synthace’s offering within biopharma/biotech.
Dr. Jurascheck brings with him more than twenty years of experience spanning senior technology roles in high-tech product companies and consultancies.
Two European leaders in biopharma and integrative software are working together to advance drug discovery.
Synthace seeks to support the development and adoption of standards and FAIR (findable, accessible, interoperable and reusable) working practices.
Scientists using the new ELISA feature in Antha reported 70% reduction in method programming time and 81% reduction in assay design and analysis time.
An exclusive look into how Synthace’s Antha bioprocess informatics reduces resource demand from data generation to interpretation by 94%.
Synthace Ltd. is pleased to announce it has released a new comprehensive whitepaper entitled "Computer-Aided Biology: The Metadata Responsibility".
